你即將離開本站

並前往https://www.prnewswire.com/news-releases/karyopharm-announces-phase-3-siendo-study-meets-primary-endpoint-with-statistically-significant-increase-in-progression-free-survival-in-patients-with-advanced-or-recurrent-endometrial-cancer-301477528.html

Karyopharm Announces Phase 3 SIENDO ... - PR Newswire

PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, ...

確定！ 回上一頁

查詢 「IARC Group 3」的人也找了：

  1. IARC Group 3
    2.
  2. iarc分類
    3.
  3. iarc分類2021
    4.
  4. iarc分類2020
    5.
  5. IARC Group 1
    6.
  6. IARC 2A
    7.
  7. IARC 2B
    8.
  8. Carcinogen
    9.